Menitorix ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-011523-31-GB
(EUCTR)
23/06/200916/04/2009A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACA study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis
MedDRA version: 9.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10046859;Term: Vaccination
Trade Name: Menitorix
Trade Name: Pneumovax II
Trade Name: REVAXIS
R & D, Cambridge University HospitalsNULLNot RecruitingFemale: yes
Male: yes
60United Kingdom